Fatty Liver Disease - Pipeline Review, H2 2015

Date: September 23, 2015
Pages: 148
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FBC324A002BEN
Leaflet:

Download PDF Leaflet

Fatty Liver Disease - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Fatty Liver Disease - Pipeline Review, H2 2015’, provides an overview of the Fatty Liver Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Fatty Liver Disease Overview
Therapeutics Development
Pipeline Products for Fatty Liver Disease - Overview
Pipeline Products for Fatty Liver Disease - Comparative Analysis
Fatty Liver Disease - Therapeutics under Development by Companies
Fatty Liver Disease - Therapeutics under Investigation by Universities/Institutes
Fatty Liver Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fatty Liver Disease - Products under Development by Companies
Fatty Liver Disease - Products under Investigation by Universities/Institutes
Fatty Liver Disease - Companies Involved in Therapeutics Development
Arisaph Pharmaceuticals, Inc.
ChemoCentryx, Inc.
Conatus Pharmaceuticals Inc.
Daewoong Pharmaceutical Co., Ltd.
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
DURECT Corporation
Galmed International Ltd.
Generon (Shanghai) Corporation Ltd.
Genovate Biotechnology Co., LTD.
Gilead Sciences, Inc.
Huons Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Metabolic Solutions Development Company, LLC
Nimbus Therapeutics, LLC
Novartis AG
Protalix BioTherapeutics, Inc.
Raptor Pharmaceuticals Corp.
Sancilio & Company, Inc.
TCM Biotech International Corp
Tobira Therapeutics, Inc.
Verva Pharmaceuticals Limited
Viking Therapeutics, Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited
Fatty Liver Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aramchol - Drug Profile
ARI-3037MO - Drug Profile
C-10 - Drug Profile
CCX-872 - Drug Profile
cenicriviroc mesylate - Drug Profile
cysteamine DR - Drug Profile
DMX-300 - Drug Profile
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
DUR-928 - Drug Profile
DWP-10292 - Drug Profile
emricasan - Drug Profile
etanercept biosimilar - Drug Profile
F-652 - Drug Profile
HU-002 - Drug Profile
KDT-501 - Drug Profile
MAT-8800 - Drug Profile
MB-12066 - Drug Profile
methazolamide - Drug Profile
MN-002 - Drug Profile
MSDC-0602 - Drug Profile
MT-2 - Drug Profile
NDI-010976 - Drug Profile
norursodeoxycholic acid - Drug Profile
oltipraz - Drug Profile
PCBB-7 - Drug Profile
pradigastat sodium - Drug Profile
Px-102 - Drug Profile
Px-103 - Drug Profile
Px-104 - Drug Profile
Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile
RT-230 - Drug Profile
saroglitazar - Drug Profile
SC-410 - Drug Profile
Small Molecule for Fatty Liver Disease - Drug Profile
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile
Small Molecule to Inhibit Them1 for Metabolic, Immunology and Gastrointestinal Diseases - Drug Profile
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile
TCM-606F - Drug Profile
VK-2809 - Drug Profile
VVP-100-X - Drug Profile
ZGN-839 - Drug Profile
Fatty Liver Disease - Recent Pipeline Updates
Fatty Liver Disease - Dormant Projects
Fatty Liver Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Fatty Liver Disease, H2 2015
Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Fatty Liver Disease - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015
Fatty Liver Disease - Pipeline by ChemoCentryx, Inc., H2 2015
Fatty Liver Disease - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
Fatty Liver Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Fatty Liver Disease - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015
Fatty Liver Disease - Pipeline by Dr. Falk Pharma GmbH, H2 2015
Fatty Liver Disease - Pipeline by DURECT Corporation, H2 2015
Fatty Liver Disease - Pipeline by Galmed International Ltd., H2 2015
Fatty Liver Disease - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
Fatty Liver Disease - Pipeline by Genovate Biotechnology Co., LTD., H2 2015
Fatty Liver Disease - Pipeline by Gilead Sciences, Inc., H2 2015
Fatty Liver Disease - Pipeline by Huons Co., Ltd., H2 2015
Fatty Liver Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Fatty Liver Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2015
Fatty Liver Disease - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Fatty Liver Disease - Pipeline by Novartis AG, H2 2015
Fatty Liver Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
Fatty Liver Disease - Pipeline by Raptor Pharmaceuticals Corp., H2 2015
Fatty Liver Disease - Pipeline by Sancilio & Company, Inc., H2 2015
Fatty Liver Disease - Pipeline by TCM Biotech International Corp, H2 2015
Fatty Liver Disease - Pipeline by Tobira Therapeutics, Inc., H2 2015
Fatty Liver Disease - Pipeline by Verva Pharmaceuticals Limited, H2 2015
Fatty Liver Disease - Pipeline by Viking Therapeutics, Inc., H2 2015
Fatty Liver Disease - Pipeline by Zafgen Inc., H2 2015
Fatty Liver Disease - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Fatty Liver Disease Therapeutics - Recent Pipeline Updates, H2 2015
Fatty Liver Disease - Dormant Projects, H2 2015
Fatty Liver Disease - Dormant Projects (Contd..1), H2 2015

LIST OF FIGURES

Number of Products under Development for Fatty Liver Disease, H2 2015
Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Arisaph Pharmaceuticals, Inc.
ChemoCentryx, Inc.
Conatus Pharmaceuticals Inc.
Daewoong Pharmaceutical Co., Ltd.
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
DURECT Corporation
Galmed International Ltd.
Generon (Shanghai) Corporation Ltd.
Genovate Biotechnology Co., LTD.
Gilead Sciences, Inc.
Huons Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Metabolic Solutions Development Company, LLC
Nimbus Therapeutics, LLC
Novartis AG
Protalix BioTherapeutics, Inc.
Raptor Pharmaceuticals Corp.
Sancilio & Company, Inc.
TCM Biotech International Corp
Tobira Therapeutics, Inc.
Verva Pharmaceuticals Limited
Viking Therapeutics, Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited
Skip to top


Fatty Liver Disease - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Liver Cirrhosis - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 86 pages
Hepatic (Liver) Tumor - Pipeline Review, H2 2014 US$ 1,600.00 Dec, 2014 · 31 pages

Ask Your Question

Fatty Liver Disease - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: